Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.

Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.